Add like
Add dislike
Add to saved papers

Dyrk1a Phosphorylation of α -Synuclein Mediating Apoptosis of Dopaminergic Neurons in Parkinson's Disease.

OBJECTIVE: To investigate the role of aberrant Dyrk1a expression in phosphorylation modification at the α -synuclein serine 129 (Ser129) site to analyze its molecular mechanism in mediating apoptosis of PD.

METHODS: The protein level of P- α -synuclein (Ser129), α -synuclein, Bcl-2, Bax, active caspase 3, GSK3 β , PI3K, AKT, and cyclinD1 were detected. The mRNA transcript levels of Dyrk1a and DAT and protein levels of IL-1 β , IL-6, COX-2, and TNF- α were detected.

RESULTS: P- α -synuclein (Ser129), α -synuclein, Bax, active caspase 3, GSK3 β , and cyclinD1 expressions were decreased in Dyrk1a-AAV-ShRNA ( P  < 0.05), and Bcl-2, AKT, and PI3K expressions were increased ( P  < 0.05). Increased TH protein expression was shown in Dyrk1a-AAV-ShRNA ( P  < 0.05). Dyrk1a mRNA was decreased in the Dyrk1a-AAV-ShRNA group ( P  < 0.05), and DAT mRNA was increased ( P  < 0.05). IL-1 β , IL-6, COX-2, and TNF- α protein levels were decreased in Dyrk1al-AAV-Sh-RNA ( P  < 0.05). Transcriptome sequencing showed that Fam220a, which was expected to activate STAT family protein binding activity and participate in the negative regulation of transcription through RNA polymerase II and protein dephosphorylation showed differentially upregulated expression. The untargeted metabolome showed that the major compounds in the Dyrk1a-AAV-ShRNA group were hormones and transmission mediators and the most metabolism-related pathways. Fam220a showed differentially upregulated expression, and differentially expressed genes were enriched for the neuroactive ligand-receptor interaction, vascular smooth muscle contraction, and melanogenesis-related pathways.

CONCLUSION: Abnormal Dyrk1a expression can affect α -synuclein phosphorylation modifications, and dyrk1a knockdown activates the PI3K/AKT pathway and reduces dopaminergic neuron apoptosis. It provides a theoretical basis for the group to further investigate the molecular mechanism.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app